All In Biotech

NDA 214876 · Glaxosmithkline

Zejula

Niraparib Tosylate · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Apr 26, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

208

25 Phase 3, 37 recruiting

FAERS reports

22,176

14,713 serious, 1,448 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 28, 2026.

ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.1 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.2 , 2.1 ) 1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA ‑ authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] . 1.2 Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g...

Mechanism: Niraparib is an inhibitor of PARP enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. Increased niraparib‑induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2 . Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZEJULA · NIRAPARIB TOSYLATE EQ 200MG BASE · TABLET, ORAL · Prescription
  • ZEJULA · NIRAPARIB TOSYLATE EQ 300MG BASE · TABLET, ORAL · Prescription
  • ZEJULA · NIRAPARIB TOSYLATE EQ 100MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Niraparib" as an intervention, any sponsor and status, largest first.

All 208 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,789
  • fatigue5,237
  • platelet count decreased4,145
  • constipation4,108
  • insomnia2,844
  • blood pressure increased2,458
  • headache2,372
  • off label use2,250
  • vomiting2,037
  • decreased appetite1,884
  • asthenia1,858
  • product dose omission issue1,855

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20164
20171,323
20183,278
20191,319
20203,087
20213,231
20223,628
20232,967
20242,062
2025878
2026398

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zejula (Niraparib Tosylate)

2024 spending

$224M

Beneficiaries

2,016

11,448 claims

Per beneficiary

$111,182

$598.84 per unit

View as table
YearSpending
2020$138,638,865
2021$152,013,598
2022$154,728,383
2023$161,500,239
2024$224,142,913

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 153 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.